$74bn BMS/Celgene merger finally cleared by competition regulatorsBristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 Share X$74bn BMS/Celgene merger finally cleared by competition regulatorshttps://pharmaphorum.com/news/74bn-bms-celgene-merger-finally-cleared-by-competition-regulators/
Big Pharma game heading for console release next monthA game that allows frustrated pharma industry execs to make the step up to the CEO role – Share XBig Pharma game heading for console release next monthhttps://pharmaphorum.com/news/big-pharma-game-heading-for-console-release-next-month/
Novo bolsters R&D pipeline with RNAi therapies from DicernaNovo Nordisk has further bolstered its liver disease R&D pipeline, signing a deal with US biotech Dicerna to Share XNovo bolsters R&D pipeline with RNAi therapies from Dicernahttps://pharmaphorum.com/news/novo-bolsters-rd-pipeline-with-rnai-therapies-from-dicerna/
Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial successMerck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, Share XMerck/Bayer set to challenge Novartis in heart failure after phase 3 trial successhttps://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/
Alkermes bolts on Rodin Therapeutics to bulk up thin pipelineAlkermes has agreed a $950 million deal to acquire Rodin Therapeutics, a US biotech developing drugs for neurodegenerative Share XAlkermes bolts on Rodin Therapeutics to bulk up thin pipelinehttps://pharmaphorum.com/news/alkermes-bolts-on-rodin-therapeutics-to-bulk-up-thin-pipeline/
Roche increases IPF presence with $1.39bn Promedior buyRoche has agreed to buy US biotech Promedior, and a portfolio of drugs including a promising molecule for Share XRoche increases IPF presence with $1.39bn Promedior buyhttps://pharmaphorum.com/news/roche-looks-to-increase-ipf-presence-with-1-39bn-promedior-buy/
Janssen taps wearable tech in Invokana heart failure trialJanssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world Share XJanssen taps wearable tech in Invokana heart failure trialhttps://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/
FDA approves latest Humira near-copy, as dozens of biosimilars head for marketThe FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of Share XFDA approves latest Humira near-copy, as dozens of biosimilars head for markethttps://pharmaphorum.com/news/fda-approves-latest-humira-near-copy-as-dozens-of-biosimilars-head-for-market/
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalsThe EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’ Share XNovartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvalshttps://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/
